MedTrace Logo

Everolimus on CKD Progression in ADPKD Patients

NCT01009957 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2015-06-23

No results posted yet for this study

Summary

The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.

Conditions

  • Polycystic Kidney Diseases

Interventions

DRUG

Everolimus

0.75 mg x 2 / day

Sponsors & Collaborators

  • A. Manzoni Hospital

    lead OTHER

Principal Investigators

  • Francesco Locatelli, MD · Nephrology and Dialysis Department - A. Manzoni Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2014-01-31
Completion
2015-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009957 on ClinicalTrials.gov